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8.1
The cell view 
J.H.P. Hui, Singapore 
Is osteoarthritis appropriate clinical target for cartilage tissue 
engineering therapy? (THE CELL VIEW) 
What is Osteoarthritis Osteoarthritis (OA) is a degenerative joint 
disease, characterized by degeneration of the articular cartilage, 
hypertrophy of bone at the margins, and changes in the synovial 
membrane. OA is a consequence of mechanical and biological events 
that destabilize articular cartilage homeostasis. Scientists now 
believe osteoarthritis results from a combination of genetic 
abnormalities and joint injuries. In this disorder, an affected joint 
experiences a progressive loss of cartilage. In the early stages of the 
disease, there is a loss of proteoglycan molecules and other tissue 
components, which causes water loss. Fissures and pits appear in 
the cartilage and as the disease progresses and more tissue is lost, 
UIFDBSUJMBHFMPTFTFMBTUJDJUZBOE¿VJE*UCFDPNFTJODSFBTJOHMZQSPOF
to damage due to repetitive use and injury. To compound the 
process, other problems develop in the bone itself as the body tries 
UPSFQBJSUIFEBNBHF$MVTUFSTPGEBNBHFEDFMMTPS¿VJE¾MMFEDZTUT
NBZGPSNBSPVOEUIFCPOZBSFBTPSOFBSUIF¾TTVSFT'MVJEQPDLFUT
may also form within the bone marrow itself, causing swelling. The 
marrow, which runs up through the center of bone, is rich in nerve 
¾CFSTBOETVDIJOKVSJFTNBZCFBOJNQPSUBOUTPVSDFPGQBJOJONBOZ
osteoarthritis sufferers. Bone cells may respond to damage by 
multiplying and growing and by forming dense, misshapen plates 
around exposed areas. Application of cartilage tissue engineering 
Cartilages are poorly vascularized tissues with a very weak capacity 
for self-repair. Because cartilage is unusual in having only one single 
cell type (chondrocytes), its relative simplicity makes it an ideal 
target for repair by cartilage tissue engineering. Chondrocytes are 
highly specialized cells that secrete the extracellular matrix proteins, 
CVUUIFZBSFEJG¾DVMUUPJTPMBUFJOIVNBOTSFQMJDBUFTMPXMZBOEBSF
prone to phenotypic dedifferentiation in culture. Chondrocyte, which 
arises from the Mesenchymal Stem Cells (MSCs), is essential for 
cartilage formation and functionality. While chondrocytes represents 
only 5-10% of the total cartilage volume, they are crucial in 
maintaining a stable Extracellular Matrix (ECM) by mediating 
synthesis, assembly and degradation of matrix proteins. 
Chondrocytes anabolize and catabolize ECM macromolecules while 
the matrix in turn maintains a state of dynamic equilibrium between 
the cellular environment and the structure of the cartilage. Tissue 
engineering has been used to treat cartilage lesions caused by OA or 
other mechanical causes.Cartilage tissue engineering has two 
different approaches – one is to implant immature cartilage (with 
ECM) and another is to implant mature cartilage (without ECM). 
Growth of cartilage is explored both in vivo and in vitro in an attempt 
to verify the usefulness of cell-based tissue engineering to produce 
cartilage. Chondrocytes for engineering cartilage Brittberg et al, in 
their landmark article, proposed transplantation of autologous 
chondrocytes. This method led to encouraging results but the 
DIPOESPDZUFTMPTFFYQSFTTJPOPGDBSUJMBHFTQFDJ¾DQSPUFJOTSFTVMUJOH
JO UIF GPSNBUJPO PG ¾CSPDBSUJMBHF MBDLJOH UIF CJPMPHJDBM BOE
mechanical properties of the normal tissue. The use of chondrocytes 
IBTTFWFSBMTJHOJ¾DBOUBEWBOUBHFT"TBSFMBUJWFMZNBUVSFUFDIOJRVF
there is greater amount of information and expertise available to 
perform successful procedures. Moreover, there are many ways 
available to obtain chondrocytes. One method is to extract the cells 
from the donor cartilage tissue. Chondrocytes can also be cultivated 
in cultures to obtain larger quantities and this process can be further 
JNQSPWFECZ UIFVTFPG HFOFUJDNPEJ¾DBUJPO UPQSPEVDF JNNPSUBM
clonal cell lines. However, there are several setbacks with regards to 
the use of chondrocytes, such as morbidity at the donor site, low cell 
number upon harvest, and loss of chondrocyte markers in culture. 
For older patients with osteoarthritis, the mature chondrocytes often 
do not function well enough for tissue engineering. Compared to 
MSCs, chondrocytes have lower proliferation activity and a greater 
possibility of the loss of phenotype. This limits the regeneration of 
the cartilage tissue and the treatment process..Finally, when 
allogenic chondrocytes are used, there is a substantial possibility of 
tissue rejection as discussed in literature This leads to the use of 
MSCs as a possible better target for cartilage tissue engineering. 
Mesenchymal stem cells for engineering cartilage Stem cells remain 
possibly the best chance for repairing cartilage tissue defects. They 
can come from two sources, namely embryonic stem cells and 
mesenchymal stem cells. Embryonic stem cells have been widely 
studied for their totipotency and regenerative ability. Despite its 
great therapeutic potential, the use of such stem cells remain 
controversial. Terotoma formation, immunogenecity and ethical 
problems were some of the reasons why clinical research in recent 
years are headed towards the use of adult stem cells (ASCs) such as 
mesenchymal stem cells. Mesenchymal stem cells can be easily 
recovered from a wide variety of adult human tissues. They have the 
capacity to differentiate toward chondrocytes and have an extensive 
self-renewal potential. Much effort has been focused on engineering 
cartilage with MSCs, but it is still a long way from clinical application. 
Initially discovered at the bone marrow, MSCs are stromal cells that 
support hematopeiesis, and have the ability to give rise to many 
lineages such as myoblasts, hepatocytes, adipocytes, osteoblasts 
BOEDIPOESPDZUFT.4$TXFSF¾STUJTPMBUFEJOUIFCPOFNBSSPXCVU
subsequently isolated in several locations such as adipose tissue, 
cryo-preserved umbilical cord blood, human exfoliated deciduous 
teeth, skin and even peripheral blood. The isolation of ASCs from 
peripheral blood and adipose tissue may represent a safe and 
accessible source of cells for tissue engineering. Experiments have 
shown that MSC-induced chondrogenesis takes place in vitro with 
TGF-beta and a three-dimensional culture environment. Bone 
morphogenic proteins (BMPs) and the Sonic hedgehog gene were 
found to enhance chondrogenesis when transfected into ASCs. 
Insulin-like growth factor was also shown to have a synergistic effect 
with a member of the TGF-beta family in promoting progenitor cell 
DIPOESPHFOFTJT -BTUMZ ¾CSPCMBTU HSPXUI GBDUPS BMTP IFMQT JO
chondrogenesis, inducing MSC proliferation and promoting retention 
of multi-lineage differentiation capacity. There is an expansion of 
knowledge on the characteristics and stimuli for chondro-induction 
of these cells in vitro. All these point toward the increasing relevance 
PG.4$TJOUIF¾FMEPGUJTTVFFOHJOFFSJOHGPSDBSUJMBHFSFQBJS4UFN
cells derived from the bone marrow and the adipose tissue express 
BTJNJMBSBOUJHFOQSP¾MFFYDFQU4USPBOEUIFTFNBSLFSTJODMVEF$%
13, CD44, CD54, CD55, CD105 and CD166. Chondrogenic potential is 
likely to be related to the expression of CD105 which is a receptor for 
TGF-beta. Hence, MSCs derived from bone marrow and adipose 
tissue show similar chondrogenic properties. Apart from undergoing 
chondrogenesis in vitro, MSCs have proven to be able to undergo 
differentiation in vivo. When transplanted into non-
JNNVOPDPNQSPNJ[FE BOJNBMT IVNBO.4$TVOEFSHP TJUFTQFDJ¾D
differentiation into multiple lineages and persist for long periods of 
time. The results of recent experiments appeared to be fairly 
promising. Tissue regeneration was found even when implants were 
placed in joints that had already progressed to OA. Cartilage injuries 
can be effectively repaired using tissue engineering, and 
osteoarthritis does not inhibit the regeneration process. Investigators 
have concluded that three-dimensional hyaline cartilage can be 
engineered using BMSCs from patients with OA. This method could 
thus be used for the repair of cartilage lesions. Studies have recently 
demonstrated the existence of a fast-growing multi- potential MSC 
population from bone marrow samples of patients with OA. Therefore, 
despite a supposedly smaller stem cell compartment in these 
patients, it is demonstrated that they can still yield a potentially 
therapeutically useful source of syngeneic MSCs. Mesenchymal 
stem cells have proven to be effective in both bone and cartilage 
SFHFOFSBUJPO HJWFO UIFJS TJUFTQFDJ¾D EJGGFSFOUJBUJOH BCJMJUZ XIJDI
may prove to be useful in the context of osteoarthritis. In an 
experiment with rabbits with osteochondral defects, transplanted 
synovium-derived MSCs were seen to differentiate into chondrocyte-
like cells while some transplanted cells in the deeper zone also 
differentiated into bone cells. The border between the bone and 
cartilage moved up and integration between original and regenerated 
cartilage tissue were improved. Such observations prove the 
usefulness of stem cells in the context of OA. However, the change in 
tidemark and the subchondral plate may involve a problem with 
regard to restoration to the original tidemark and may result in long-
term failures of repair procedure. This phenomenon is also seen in 
humans and best described as microfracture . MSCs have not been 
proven to be too successful on several occasions. Implantation of 
VONPEJ¾FE.4$TIBTCFFO SFQPSUFE UP SFQBJS DBSUJMBHFEFGFDUT JO
rabbits but the implantation of uncommitted cells often leads to 
¾CSPDBSUJMBHF GPSNBUJPO JOEJDBUJOH UIBU UIF JOWJWPFOWJSPONFOU JT
OPU TVG¾DJFOU UP QSPNPUF DIPOESPHFOFTJT %FTQJUF UIF HSPXJOH
information regarding MSCs and their use in cell-based strategies, 
the mechanisms that preside over MSC self-renewal and multi-
lineage differentiation are not substantially understood and require 
active investigation. Successful outcome of cell-based cartilage 
tissue engineering ultimately depends on the proper differentiation 
of stem cells into chondrocytes and the assembly of the appropriate 
cartilaginous matrix to achieve the load-bearing capabilities of the 
natural articular cartilage. Multiple requirements, including growth 
GBDUPST TJHOBMJOH NPMFDVMFT BOE QIZTJDBM JO¿VFODFT OFFE UP CF
met. Adult mesenchymal stem-cell-based tissue engineering is a 
promising technology for the development of a transplantable 
cartilage replacement to improve joint function. 
Osteoarthritis – a disease of the joint or the cartilage? One can argue 
that OA is an appropriate clinic target for cartilage tissue engineering 
in that it involves the degeneration of the articular cartilage which the 
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tissue engineering aims to rectify. In many early cases of OA, it has 
CFFOJEFOUJ¾FEUIBUUIFMPTTPGDBSUJMBHFUJTTVFJTUIFNBJOTZNQUPN
Since the initial stages of OA involve increased cell proliferation 
and synthesis of matrix proteins, proteinases and cytokines in the 
cartilage, laboratory investigations have focused on the chondrocyte 
as a target for therapeutic intervention. However, it is known that 
adult articular chondrocytes have limited capacity to regenerate the 
normal cartilage matrix and the damage is irreversible unless the 
destruction process is interrupted. However, OA is not appropriate 
for tissue engineering based on our knowledge of this joint disease. 
In order to answer the question whether OA is an appropriate clinical 
UBSHFU GPS DBSUJMBHF UJTTVF FOHJOFFSJOH XF NVTU ¾STU MPPL BU UIF
pathogenesis of OA. Many studies have shown that osteoarthritis 
affects not only the cartilage but both the subchondral bone and the 
TZOPWJBM¿VJE"TUVEZTIPXFE UIBUTVCDIPOESBMCPOF SFNPEFMJOH
plays an important role in the pathogenesis of OA, showing that it 
is not merely a cartilage disorder. ALN or other inhibitors of bone 
resorption could potentially be used as disease-modifying agents in 
the treatment of OA. By employing cartilage tissue engineering, the 
micro-environment in the synovial space remains largely unchanged 
BOEJUJTMJLFMZUIBUUIFJO¿BNNBUJPOBOEEFHSBEBUJPOPGUIFDBSUJMBHF
will persist despite attempts at tissue engineering. Hence, cartilage 
tissue engineering, which only addresses the issue of cartilage 
degeneration, seems to be unable to tackle the problems brought 
about by advanced stages of OA. Even in cases of early OA, research 
has shown in equine joints that distinct biochemical changes 
were detected in the cartilage, subchondral and trabecular bone, 
suggesting that OA is more than a simple case of cartilage defect 
brought about by degeneration. Next stage – Gene therapy? At later 
stages, cartilage tissue engineering with or without gene therapy 
XJUIBOBCPMJDGBDUPSTXJMMBMTPSFRVJSFUIFSBQZUPJOIJCJUJO¿BNNBUJPO
and block damage to newly repaired cartilage. Recent studies have 
proven that people may be genetically pre-disposed to OA, which 
points towards the presence of certain genes. Tissue engineering as a 
treatment for osteoarthritis is extremely challenging. Transplantation 
PGHFOFUJDBMMZNPEJ¾FEDFMMTJTBOJOUFSFTUJOHDPODFQUCBTFEPOUIF
production of therapeutic proteins directly at the target site. 
Conclusion Cell therapy will be a viable treatment option. However 
we will also need to employ scaffolds and growth factors to help 
solve the problems of both the bone and the cartilage prevalent in 
osteoarthritis. 
8.2
Will regenerated cartilage slow down the disease process in 
osteoarthritis?
A.P. Hollander8,B¾FOBI88ZMEF"#MPN6OJUFE,JOHEPN
The use of cells to repair articular cartilage is at an exciting stage 
of development as an approach to the treatment of joint disorders. 
Until now the application of autologous chondrocyte implantation 
(ACI) has been largely restricted to the repair of focal lesions and 
osteoarthritis (OA) has been considered as an exclusion criterion. 
However cartilage repair methods are generally becoming more 
sophisticated and the technology for growing mature cartilage using 
stem cells derived from older OA patients is now quite advanced. 
These advances in our technological capabilities have brought in to 
sharp focus the question of which OA patients if any we should treat 
using cartilage regeneration.
It is often argued that knee arthroplasty is such a successful 
operation that there is no need for a biological therapy. There is 
no doubt that those companies selling joint prostheses would 
encourage us to subscribe to this view. However there are three 
important reasons to challenge this dogma:
1. The subjective patient experience of a prosthesis may not 
match objective measurements of prosthesis survival or measures 
of improvement in range of motion and knee stability. In order to 
address this question we have recently undertaken a survey of 1725 
OA patients in the Bristol area 5-8 years after primary, unilateral hip 
or knee replacement surgery. The Oxford questionnaire was used 
to measure the patients’ experiences of pain and functional ability. 
In this way we have been able to show that patients who have 
VOEFSHPOFUPUBMLOFFSFQMBDFNFOUIBWFBTJHOJ¾DBOUMZXPSTF0YGPSE
score (more pain and less function) than those who have undergone 
UPUBMIJQSFQMBDFNFOU5IFTF¾OEJOHTBSFJOBDDPSEBODFXJUIPUIFS
studies of joint function after arthroplasty and raise concerns about 
UIFFG¾DBDZPGUPUBMLOFFSFQMBDFNFOUJOUIFUSFBUNFOUPG0"
2. Arthroplasty is now being used to treat much younger patients 
than was originally intended and this is likely to lead to a large 
increase in the numbers of patients requiring secondary and even 
tertiary implants following asceptic loosening. Delaying the time of 
UIF¾STUQSPTUIFTJTJNQMBOUBUJPOCZUIFVTFPGCJPMPHJDBMUIFSBQJFT
could play an important part in containing this problem.
3. There are growing concerns over the safety of implanting metal 
on metal prosthesis, particularly in younger patients, because of the 
generation of metallic wear debris that may directly induce genetic 
toxicity. Because the use of these implants in younger patients 
is a relatively recent phenomenon, we have not yet accumulated 
enough epidaemiological data to determine if arthroplasty is 
associated with increased carcinogenesis or with an increased 
incidence of congenital malformations where they have been 
implanted in women or men of child-bearing age. However it is clear 
that metal wear is capable of causing karyotpic changes that could 
theoretically lead to tumourogenesis or congenital defects.
Given these concerns, it makes sense to consider the possibility 
of using biological therapies that may be less invasive and more 
acceptable to younger OA patients. Until now exploration of this 
approach has been restricted to the realm of cartilage regeneration, 
with little regard for modifying the subchondral bone or the soft 
tissues of the joint. This focus on cartilage has been used as an 
argument against biological therapy. It is often suggested with 
HSFBU DPO¾EFODF UIBU SFQMBDJOH UIF DBSUJMBHFXJUIPVU UBDLMJOH UIF
underlying OA pathology is a waste of time. This may or may not 
be true. The assumption in this view of the world is that replacing 
DBSUJMBHFXPVMEIBWFOPJO¿VFODFPOUIFCJPMPHZPGUIFTVSSPVOEJOH
tissues. However it is equally possible that the very act of implanting 
new cartilage may lead to effective remodelling of other tissues and 
renewed joint stability. No doubt also there will be many patients 
who will require a combination of cartilage implantation and some 
other intervention (for example osteotomy to realign the joint and 
off-load the implant) in order to respond well to the newly engineered 
tissue. In an effort to begin to addres the question of whether or not 
implanted cartilage can survive and grow in an OA joint, we recently 
undertook a study of second look biopsies from patients treated 
with the Hyalograft C autologous chondrocyte therapy for focal knee 
DBSUJMBHFEFGFDUT8FJEFOUJ¾FEBTVCHSPVQPGUIFTFQBUJFOUTXIP
had X-ray evidence of pre-existing OA at the time of implantation. 
We therefore asked if the cartilage regenerated in these OA knees 
was of worse quality than that regenerated in the knees of patients 
with no evidence of OA at the time of implantation. Surprisingly 
we found that if anything the cartilage formed in the OA knees 
